Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Continuous glucose monitoring enhanced by geriatric care principles reduced the duration of hypoglycemia without worsening ...

TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

Trinity Biotech today announced that it completed the first pre-pivotal clinical trial in Europe for its next-generation CGM ...

Continuous Glucose Monitoring Devices Market to reach a value of US$ 12.51 Bn by 2031 at a CAGR of 9.9% between 2024 and 2031 BURLINGAME, CA, UNITED STATES, October 15, 2024 /EINPresswire / -- A ...

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

A device used by diabetics is now over-the-counter, making it easier for people to get. The device could be so helpful, so diabetics could get off their medications. The device is called a CGM or ...

Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...